BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 7707113)

  • 1. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
    Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
    J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.
    Kubota K; Tamura T; Fukuoka M; Furuse K; Ikegami H; Ariyoshi Y; Kurita Y; Saijo N
    Ann Oncol; 2000 Apr; 11(4):445-50. PubMed ID: 10847464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
    Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
    Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
    Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
    Furuse K; Fukuoka M; Kawahara M; Nishikawa H; Takada Y; Kudoh S; Katagami N; Ariyoshi Y
    J Clin Oncol; 1999 Sep; 17(9):2692-9. PubMed ID: 10561343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
    Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer.
    Atagi S; Kawahara M; Hosoe S; Ogawara M; Kawaguchi T; Okishio K; Naka N; Sunami T; Mitsuoka S; Akira M
    Lung Cancer; 2002 Apr; 36(1):105-11. PubMed ID: 11891041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
    J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
    Wagner H; Lad T; Piantadosi S; Ruckdeschel JC
    Chest; 1994 Dec; 106(6 Suppl):348S-354S. PubMed ID: 7988262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
    J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
    Burkes RL; Ginsberg RJ; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Cooper JD
    J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer].
    Nakano K; Kumagai K; Ishida H; Kohjima N; Hiramoto T; Hada Y
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):57-61. PubMed ID: 8546470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306.
    Sekine I; Nishiwaki Y; Ogino T; Yokoyama A; Saito M; Mori K; Tsukiyama I; Tsuchiya S; Hayakawa K; Yoshimura K; Ishizuka N; Saijo N
    J Clin Oncol; 2002 Feb; 20(3):797-803. PubMed ID: 11821463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
    Van den Brande P; De Ruysscher D; Vansteenkiste J; Spaas P; Specenier P; Demedts M
    Lung Cancer; 1998 Oct; 22(1):45-53. PubMed ID: 9869107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.